Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Biogen Idec Posts Higher Q1 Profit; Ups 2013 Targets - Quick Facts

RELATED NEWS
Trade BIIB now with 

Biogen Idec Inc. (BIIB: Quote) reported an improvement in first-quarter 2013 GAAP net income to $426.75 million, or $1.79 a share, from $302.66 million, or $1.25 a share, a year earlier. According to non-GAAP basis, net income attributable to Biogen Idec was $469.4 million, or $1.97 a share, the company added. On average, 26 analysts polled by Thomson Reuters expected earnings per share of $1.61 for the quarter. Analysts' estimates typically exclude one-time items.

Quarterly total revenues of $1.42 billion, were 10% higher than $1.29 billion in the first quarter of 2012. Analysts estimated revenues of $1.42 billion for the quarter.

For full year 2013, the company now sees non-GAAP earnings per share between $7.80 and $7.90, GAAP earnings per share between $6.69 and $6.79, as well as revenue growth to be around 16% - 18%. Earlier Biogen expected fiscal 2013 adjusted earnings of $7.15 - $7.25 per share on projected revenue growth of about 10 percent. Analysts project annual earnings of $7.79 per share.

Click here to receive FREE breaking news email alerts for Biogen Idec and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Proctor and Gamble (PG) has sold two of its soap brands to European consumer products giant Unilever (UN). Cincinnati-based P&G says the sale includes the global Camay brand, the Zest brand outside of North America and its Talisman manufacturing plant in Mexico. The plant employs approximately... Dish Network is no longer carrying Fox News in yet another dispute for the television provider. Fox News, which changed the face of cable news with its ardent advocacy of conservative issues, went dark Sunday, replaced on Dish by The Blaze, Glen Beck's new right-leaning channel. Fox Business channel... Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.